1,001 reports of this reaction
2.2% of all LAMIVUDINE ORAL reports
#9 most reported adverse reaction
TREATMENT FAILURE is the #9 most commonly reported adverse reaction for LAMIVUDINE ORAL, manufactured by Apotex Corp.. There are 1,001 FDA adverse event reports linking LAMIVUDINE ORAL to TREATMENT FAILURE. This represents approximately 2.2% of all 44,876 adverse event reports for this drug.
Patients taking LAMIVUDINE ORAL who experience treatment failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TREATMENT FAILURE is a less commonly reported adverse event for LAMIVUDINE ORAL, but still significant enough to appear in the safety profile.
In addition to treatment failure, the following adverse reactions have been reported for LAMIVUDINE ORAL:
The following drugs have also been linked to treatment failure in FDA adverse event reports:
TREATMENT FAILURE has been reported as an adverse event in 1,001 FDA reports for LAMIVUDINE ORAL. This does not prove causation, but indicates an association observed in post-market surveillance data.
TREATMENT FAILURE accounts for approximately 2.2% of all adverse event reports for LAMIVUDINE ORAL, making it a notable side effect.
If you experience treatment failure while taking LAMIVUDINE ORAL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.